<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03859128</url>
  </required_header>
  <id_info>
    <org_study_id>JS001-016-III-HCC</org_study_id>
    <nct_id>NCT03859128</nct_id>
  </id_info>
  <brief_title>Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection</brief_title>
  <acronym>JUPITER 04</acronym>
  <official_title>A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Toripalimab (Recombinant Humanized Anti-PD-1 Monoclonal Antibody, JS001) Versus Placebo as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence Following Radical Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Junshi Bioscience Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Junshi Bioscience Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate if Toripalimab (A PD-1 Inhibitor) will improve recurrence-free&#xD;
      survival (RFS) compared to placebo in participants with HCC and are at high risk of&#xD;
      recurrence after complete resection with no residual of tumour.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 5, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 18, 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BICR-RFS</measure>
    <time_frame>Time frame is up to 31 months (for interim analysis, up to 44 months for Primary analysis)</time_frame>
    <description>Defined as the time from randomization to the first documented disease recurrence or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator-RFS</measure>
    <time_frame>up to 44 months</time_frame>
    <description>the time from randomization to the date of the first documented progressive disease (tumor evlauation by BICR in accordance with RECIST 1.1), or to the date of death for any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-month recurrence-free survival rate (RFS12)</measure>
    <time_frame>up to 44 months</time_frame>
    <description>probability of patients without recurrence or death for any cause at Month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-month recurrence-free survival rate (RFS24)</measure>
    <time_frame>up to 44 months</time_frame>
    <description>probability of patients without recurrence or death for any cause at Month 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence (TTR)</measure>
    <time_frame>up to 44 months</time_frame>
    <description>the time from randomization to the first documented disease recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to local recurrence (TTLR)</measure>
    <time_frame>up to 44 months</time_frame>
    <description>the time from randomization to the first documented local disease recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 44 months</time_frame>
    <description>the time from randomization to death for any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12- and 24-month overall survival rate (OS12 and OS24)</measure>
    <time_frame>up to 44 months</time_frame>
    <description>probability of patients surviving at Month 12 and 24, respectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs</measure>
    <time_frame>up to 44 months</time_frame>
    <description>Incidence of AEs (including SAEs and AESIs) is evaluated by the investigator, and severity is determined in accordance with CTCAE v5.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">402</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TORIPALIMAB 240mg ,Q3W, up to 16 Weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 240mg Q3W, up to 16 Weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TORIPALIMAB INJECTION(JS001 )</intervention_name>
    <description>Arm A: Toripalimab 240mg IV(Injection of Vein) Q3W Arm B: Placebo 240mg IV(Injection of Vein) Q3W</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. HCC with at least one protocol defined risk factor, diagnosed confirmed by central&#xD;
             pathological review and received R0 resection;&#xD;
&#xD;
          2. BICR confirmed no resdual tumor lesions are detected in liver;&#xD;
&#xD;
          3. Child-Puch score, Class A;&#xD;
&#xD;
          4. ECOG score is 0;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients previously received PD-1 antibody, PD-L1 antibody, PD-L2 antibody or CTLA-4&#xD;
             antibodies, including those who have participated in the JS001 clinical study;&#xD;
&#xD;
          2. Portal vein tumor thrombi or liver metastases or recurrent liver cancer;&#xD;
&#xD;
          3. With symptoms of central nervous system metastasis;&#xD;
&#xD;
          4. With any history of active autoimmune disease or autoimmune disease;&#xD;
&#xD;
          5. Known liver diseases with clinical significance;&#xD;
&#xD;
          6. Patients infected by hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D&#xD;
             virus (HDV):&#xD;
&#xD;
        Other protocol defined inclusion/exclusion criteria could apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Zhongshan Hospital,Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>February 18, 2019</study_first_submitted>
  <study_first_submitted_qc>February 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2019</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

